Manolo Bellotto, PhD, General Manager and President Gain Therapeutics and is dedicated to redefining drug discovery through the use of supercomputers and proprietary algorithms to understand rare diseases and diseases where there is a high medical need related to protein misfolding. These indications include cancer, neurodegenerative, metabolic and inflammatory diseases.
While traditional drug discovery around protein misfolding was through high-throughput screening, Gain can efficiently identify a select group of molecules that can potentially correct misfolding or induce misfolding of specific proteins. In a short period of time, using a personalized approach in each different target, they have the biological characterization to see if they can intervene on the protein, potentially leading to a pharmacological solution.
Gain Therapeutics Website